Canopy Growth Corporation (CGC) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.65 -3.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.64

Canopy Growth Corporation (CGC) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $285.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CGC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CGC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Canopy Growth Corporation (NASDAQ: CGC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.65 (-3.33% 1D, market cap $285.6M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, CGC ranks #504 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CGC compare to USNA and SNDL in the Health Care sector?
▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CGC carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $265.0M) and SNDL (SNDL Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CGC?
▼

Per CGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001737927), Canopy Growth Corporation generated $0 in revenue, -$189.0M in net income, and $0 in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.64 (-0.79%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (11)Whales (6)SEC (10)Macro (7)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
$3 Bull$1 Base$0 Bear
📬 FREE CGC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGC)Realized 20D OHLCV Swing Band: ±11.9%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY CGC SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+11/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($8.0M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
49
Grade D$0.76-5.3% Next Q
Q2 (-2Q)
46
Grade D$0.72-6.9% Next Q
Q3 (-1Q)
44
Grade D$0.67-3% Next Q
Current
41
Grade D-$0.65-7.2% Hist 90D α
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CGC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CGC currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.86) and Max Pain ($0.68) forces dealer call-delta covering toward $2.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CGC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CGC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CGC Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CGC)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CGC. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CGC)

  • ✓Walkthrough of CGC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CGC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.91%🛡️ HOLDING TREND SUPPORT
2026-11-02O $0.68H $0.68L $0.65C $0.65VOL 1.13M
RES: $1.03SUP: $0.63SMA50: $0.86SMA200: $1.00
$1.26$1.09$0.92$0.76$0.59RES $1.03SUP $0.63$0.652026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CGC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CGC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CGC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CGC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGC)

Health Care Rank #504 of 1016 ⚔️ USNA vs CGC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CGC vs. USNA, SNDL, ACB, OBIO)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Canopy Growth Corporation (CGC) ranks #504 by composite RQD confidence (41/100, grade D-) and #526 by equity capitalization ($285.6M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. ACB currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with CGC at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CGC ACTIVE
Canopy Growth Corporation
D- 41/100 — — — -3.33% $285.6M Benchmark Subject
USNA
USANA Health Sciences Inc.
D 50/100 24.6x 78.3% 7.9% -0.21% $265.0M /usna-vs-cgc →
SNDL
SNDL Inc.
D 48/100 — — — -4.61% $316.3M /sndl-vs-cgc →
ACB
Aurora Cannabis Inc.
D+ 54/100 — — — -0.49% $252.8M /acb-vs-cgc →
OBIO
Orchestra BioMed Holdings Inc.
D- 36/100 — 96.0% -35.0% -2.96% $366.0M /obio-vs-cgc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001737927

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Canopy Growth Corporation (CGC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$189.0M, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, CGC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $0 -$189.0M — — — —
FY2024 (FY) 2025-03-31 $0 -$354.0M — — — —
FY2023 (FY) 2024-03-31 $0 -$526.0M — — — —

3. CGC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CGC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Canopy Growth Corporation (NASDAQ: CGC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.65 (-3.33% 1D, market cap $285.6M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, CGC ranks #504 in composite RQD confidence.

How does CGC compare to USNA and SNDL in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CGC carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $265.0M) and SNDL (SNDL Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CGC?

Per CGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001737927), Canopy Growth Corporation generated $0 in revenue, -$189.0M in net income, and $0 in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CGC trading relative to its 50-day, 200-day, and 52-week technical levels?

CGC last traded at $0.65 (-3.33% on volume of 2,281,510 shares), positioning the stock -24.42% below its 50-day simple moving average ($0.86) and -35.00% below its 200-day simple moving average ($1.00). Across its 52-week range of $0.64 to $2.38, CGC sits at the 0.6% percentile with a 14-day RSI of 33.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($1.00 to $0.73).

CGC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CGC insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CGC leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CGC — Canopy Growth Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:39:07Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CGC scores 41 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 11 / 20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 6 / 20 (institutional accumulation and options positioning), Insider Conviction at 7 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 7 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).

Taken together, the pillar scores point to weakness across cash generation, institutional and insider support, and balance-sheet strength. The fundamental pillar reflects a 0% ROIC and 0% FCF yield, meaning the source data does not show the business currently converting capital into cash returns. The Piotroski F-Score of 1 out of 9 is a low reading on the forensic checklist. The Altman Z-Score of 2.5 is reported alongside it, and the Debt/Equity of 0.5 provides some context on leverage. For a prospective investor, the upside case would need to rest on a turnaround in cash generation or a shift in flow data, neither of which is demonstrated in the supplied figures. Valuation tradeoffs cannot be fully assessed because P/E, Forward P/E, EV/EBITDA, and EPS are not available in source data. The verdict and pillar breakdown are educational indicators of the rating framework, not personalized financial advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$0.0M$-189.0MN/AN/AN/AN/A
FY 2024$0.0M$0.0M$-354.0MN/AN/AN/AN/A
FY 2023$0.0M$0.0M$-526.0MN/AN/AN/AN/A

Per the SEC financials, reported net income was $-526.0M for FY 2023, $-354.0M for FY 2024, and $-189.0M for FY 2025, with revenue and operating income each shown as $0.0M across all three periods. Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is 0%. The Forensic Balance Sheet pillar cites an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and Debt/Equity of 0.5 per the Roarable RQD rating. Cash and debt balances are N/A in the financial periods provided.

Recent Catalysts & News Wire Analysis

Six headlines are provided, all tagged with a GREEN light and CATALYST impact label, and all related to CGC:

  • A Yahoo Finance report on the stock dipping more than the broader market.
  • A Yahoo Finance report on the stock declining while the market improves.
  • A TradingView report on shareholders approving reverse split authority and electing the board.
  • A kalkine.ca report on downside pressure and a cautious outlook.
  • A Stock Titan report that, after 30 business days below $1, CGC received a compliance deadline from Nasdaq.
  • A Mugglehead Investment Magazine report that shareholders authorized up to a 1-for-15 reverse split.

Risk watch items in the news flow center on the sub-$1 trading period, the associated compliance deadline, and the authorized reverse split. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Open Questions

  • What is the company's revenue and operating income trajectory, given that the source reports $0.0M for each period, and what drives the reported net losses?
  • How does the 1-for-15 reverse split authorization interact with the Nasdaq compliance deadline, and what is the timing of any implementation?
  • What are cash and debt balances, and how do they reconcile with the reported Debt/Equity of 0.5 and Altman Z-Score of 2.5?
  • What are forward earnings or EBITDA expectations, given that P/E, EPS, and EV/EBITDA are not available?
  • What institutional and insider positioning exists behind the cited 13F and Form 4 flow pillar scores?

CGC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Canopy Growth Corporation (CGC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CGC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CGC Bull vs. Bear Conversation Board — What's Your Call at $0.65?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CGC 🐻 67% BEARISH CONVICTION
1. Pick Your Side on CGC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.60 (-11.8%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CGC (D- • RQD 41/100) a Buy at $0.68?

Welcome to the CGC (Canopy Growth Corporation) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.53 (-22.1%)
Spot @ $0.68

Pump the brakes on CGC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CGC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Canopy Growth Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.78 (+14.7%)
Spot @ $0.68

CGC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CGC, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $0.68 (52-wk range $0.64 - $2.38), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%